The author was motivated to write this important book because currently there is no systematically-written document on the ZIKV disease, which could serve at this crucial moment as a textbook for medical students, physicians, nurses, and other healthcare providers as well as a reference book for basic researchers, professors, and the general public. The original concept of ZIKV-Charnolopathy due to compromised mitochondrial bioenergetics in highly vulnerable (neural progenitor cells, spermatocytes, oocytes etc.) cells and its amelioration by physiological and/or pharmacological interventions is based on years of research experience. This book describes unique organ and disease-specific Charnoly body (CB) inhibitors, charnolophagy inducers, CB sequestration inhibitors, and chanolophagosome stabilisers as promising charnolopharmacotherapeutics. They are meant to aid in the prevention and treatment of the ZIKV-linked diversified spectrum of neurodevelopmental anomalies (embryopathies) in newborn infants and Guillain Barre Syndrome (GBS) in adults. Clinical management of ZIKV-induced GBS employing IV immunoglobulin and plasmapheresis (plasma exchange) is also described.